2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-171464
    Lp(a)-IN-5 2924841-79-0 98%
    Lp(a)-IN-5 (Compound A) is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 inhibits the assembly of Apo(a) and ApoB proteins with an IC50 value of 0.41 nM. Lp(a)-IN-5 is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases.
    Lp(a)-IN-5
  • HY-171782
    Amidepin 90405-00-8
    Amidepin is a new type of antiarrhythmic compound. Amidepin has the activity of regulating cardiac electrical activity. The main regulatory mechanism of amidepin involves ion channel or receptor interaction. Amidepin can be used for the study of arrhythmias.
    Amidepin
  • HY-172094
    AMPK-IN-6 98%
    AMPK-IN-6 (compound 13a) is potent AMPK inhibitor with an IC50 value of 0.093 µM. AMPK-IN-6 induces apoptosis and inhibits autophagy. AMPK-IN-6 shows antiproliferative activity. AMPK-IN-6 has the potential for the research of pulmonary arterial hypertension.
    AMPK-IN-6
  • HY-172141
    Ebio2 98%
    Ebio2 is a potent KCNQ2 activator.
    Ebio2
  • HY-172181
    NSC380324 98%
    NSC380324 is a P2Y12 receptor antagonist, possessing antiplatelet activity, and can be utilized in research on atherosclerotic cardiovascular diseases.
    NSC380324
  • HY-172227
    S-15176 148089-70-7 98%
    S-15176 is an inhibitor of the mitochondrial permeability transition pore (PTP). S-15176 inhibits mitochondrial swelling induced by tert-butylhydroperoxide with an IC50 value of 45.7 μM. S-15176 inhibits PTP opening, prevents mitochondrial membrane potential dissipation and NAD(P)H oxidation, and increases mitochondrial calcium loading capacity. S-15176 is promising for research of ischemia-reperfusion injury.
    S-15176
  • HY-172231
    Hexolame 110346-23-1 98%
    Hexolame is an estrogen receptors agonist with dual anticoagulant and estrogenic properties. Hexolame binds to estrogen receptors to induce anticoagulant effects by modulating clotting factors or platelet activity. Hexolame is promising for research of prostatic cancer and prevention of thrombosis.
    Hexolame
  • HY-172234
    PF-06842874 2516247-98-4 98%
    PF-06842874 is a CDK4/Cyclin D1 and CDK6/Cyclin D3 inhibitor (Ki values are 62 and 130 nM, respectively). PF-06842874 can be used in the research of pulmonary arterial hypertension and cancer.
    PF-06842874
  • HY-172281
    DSPE-PEG1000-CCK8 98%
    DSPE-PEG1000-CCK8 is a PEG compound which composed of DSPE and a Cholecystokinin-8 (CCK8). Cholecystokinin-8 has the activity of peptide regulating gallbladder contraction and digestive system function. DSPE-PEG1000-CCK8 can be used for drug delivery.
    DSPE-PEG1000-CCK8
  • HY-172400
    FXIa-IN-16 3046390-69-3 98%
    FXIa-IN-16 (Compound 43) is an orally active and selective Factor XIa (FXIa) inhibitor with an IC50 of 0.19 nM. FXIa-IN-16 exhibits strong anticoagulant and antithrombotic activities and shows good safety in mice. FXIa-IN-16 can be used in the research related to the treatment of thrombosis.
    FXIa-IN-16
  • HY-172417
    Becondogrel 1416696-44-0 98%
    Becondogrel (2-Oxoclopidogrel) is the metabolite of Clopidogrel (HY-15283). Becondogrel irreversibly inhibits P2Y12 receptor, thereby inhibiting platelet aggregation and thrombosis.
    Becondogrel
  • HY-172686
    DSPE-PEG1000-CSTSMLKAC 98%
    DSPE-PEG1000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG1000-CSTSMLKAC can be used for drug delivery.
    DSPE-PEG1000-CSTSMLKAC
  • HY-172687
    DSPE-PEG2000-CSTSMLKAC 98%
    DSPE-PEG2000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG2000-CSTSMLKAC can be used for drug delivery.
    DSPE-PEG2000-CSTSMLKAC
  • HY-172876
    FLY26 98%
    FLY26 is a selective partial GluN2B antagonist with an IC50 value of 0.64 μM. FLY26 partially inhibits the GluN2B subunit of NMDA receptors, reduces calcium ion influx and reactive oxygen species (ROS) production and activates the BDNF/TrkB/CREB neuroprotective signaling pathway to alleviate neuronal excitotoxicity and mitochondrial dysfunction. FLY26 is promising for research of neurological deficits caused by cerebral ischemia-reperfusion injury.
    FLY26
  • HY-172894
    G9a-IN-3 98%
    G9a-IN-3 (compound 16g) is a potent G9a inhibitor with an IC50 of 0.002 μM. G9a-IN-3 can be used in the study of sickle cell disease.
    G9a-IN-3
  • HY-172901
    AMPK activator 17 98%
    AMPK activator 17 (Compound 10g) is an orally active AMPK activator. AMPK activator 17 has significant anti-adipogenic (IC50: 3.4 μM) and dyslipidemia-modifying activities. AMPK activator 17 inhibits the early stages of adipocyte differentiation (mitotic clonal expansion) by activating the AMPK pathway. AMPK activator 17 can enhance mitochondrial function and fatty acid oxidation in mature adipocytes. AMPK activator 17 improves dyslipidemia by promoting reverse cholesterol transport. AMPK activator 17 can be used in the study of obesity and related metabolic diseases (such as type 2 diabetes and cardiovascular disease).
    AMPK activator 17
  • HY-172904
    Antidiabetic agent 15 98%
    Antidiabetic agent 15 (compound 1B15) is a AT1R and NEP dual inhibitor. Antidiabetic agent 15 reduces the oxidative stress and restores the mitochondrial membrane potential.
    Antidiabetic agent 15
  • HY-172905
    BCX-3607 885684-79-7 98%
    BCX-3607 is an orally active tissue factor/factor VIIa (TF-FVIIa) inhibitor (IC50: 4 nM). BCX-3607 blocks the extrinsic coagulation pathway by inhibiting the TF-FVIIa complex and significantly prolongs the prothrombin time (PT). BCX-3607 has a higher selectivity for TF-FVIIa than other serine proteases (such as thrombin, FXa, etc.). BCX-3607 can reduce thrombus weight and inflammatory response, and has both anti-thrombotic and anti-inflammatory effects. BCX-3607 can be used in the study of thrombosis-related diseases.
    BCX-3607
  • HY-172914
    ACLY-IN-1 2897695-26-8 98%
    ACLY-IN-1 (compound 55) is a potent ACLY inhibitor with an IC50 of 8.3 nM. ACLY-IN-1 can be used in the study of hyperlipidemia.
    ACLY-IN-1
  • HY-172942
    SP11 2629218-24-0 98%
    SP11 is a mitochondrial reactive oxygen species (ROS) inhibitor. SP11 activates Fis1 by binding to Cys41 (IC50: 9.4 µM) and increases the translocation of Drp1 to mitochondria. SP11 can be used in studies on the protection against oxidative stress damage.
    SP11
Cat. No. Product Name / Synonyms Application Reactivity